Please assess the completion status of the following clinical trial:

Trial Title: Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of rectal cancer or neoplastic polyp (i.e. intramucosal carcinoma, carcinoma in situ)~* BFI score must meet at least one of the below criteria:~  * Total BFI \< 50~ * Dietary subscale \< 11~ * Frequency subscale \< 19~ * Urgency subscale \< 12~* English speaking~* Patients ≥18 years old. age~* Sphincter-preserving surgery and ≥ 12 months after restoration of bowel continuity~Exclusion Criteria:~* Locally recurrent or metastatic disease~* Immune suppressive medication~* Seizure disorder~* Prior sacral/lower spinal surgery~* Congenital Spinal defect/Paraplegia~* Rectal prolapse~* IBD/Crohn's~* Pregnancy~* Active anal/rectal abscess~* Pacemaker or other electronic implanted device~* Immediate need for MRI~* At the time of the wire stimulation procedure, patients will be excluded if the surgeon is unable to place the temporary stimulating lead~* Inability to commit to local follow up for device management.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- InterStimTM the device on (Type: EXPERIMENTAL): The device will be set to stimulate for 4 weeks, then off for two weeks, and then the device will be on but will not stimulate for 4 weeks.
- InterStimTM the device off (Type: EXPERIMENTAL): The device will be on but will not stimulate for 4 weeks, then off for two weeks, and then the device will be set to stimulate for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).